Stay updated on Faricimab in Neovascular AMD Clinical Trial
Sign up to get notified when there's something new on the Faricimab in Neovascular AMD Clinical Trial page.

Latest updates to the Faricimab in Neovascular AMD Clinical Trial page
- Check4 days agoChange DetectedThe ClinicalTrials.gov page footer now displays site revision v3.8.1 instead of v3.8.0.SummaryDifference0.0%

- Check11 days agoChange DetectedThe study record for the TENAYA faricimab trial is displayed, including its design, eligibility criteria, locations, outcome measures, results-related publications, and study documents.SummaryDifference100%

- Check18 days agoChange DetectedThe footer now identifies the ClinicalTrials.gov site revision as v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check32 days agoChange DetectedA sitewide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence.” The site revision label advances from v3.7.1 to v3.7.2 while the page continues to display a 403 error.SummaryDifference1%

- Check46 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1; the page remains a 403 Forbidden error.SummaryDifference0.2%

- Check60 days agoChange Detected403 Forbidden page now replaces the study record, turning the page into an access-denied screen. The study details, documents, and related content are no longer visible to users.SummaryDifference18%

Stay in the know with updates to Faricimab in Neovascular AMD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Faricimab in Neovascular AMD Clinical Trial page.